Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 11/20 | 0.58 |
| ▸ | EP300 | Q09472 | 1/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.45 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | RGS4 | P49798 | 2/20 | 0.39 |
| ▸ | RGS8 | P57771 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3655957 | 0.89 | ALDH1A1 (0.57) | KAT2BEP300CREBBPKAT2AMAPT | |
| SCHEMBL6931122 | 0.86 | KAT2B (0.53) | KAT2BEP300CREBBPKAT2A | |
| SCHEMBL5593712 | 0.85 | KAT2B (0.55) | KAT2BEP300CREBBPKAT2ACA12 | |
| SCHEMBL80967 | 0.85 | KAT2B (0.58) | KAT2BMAPTRGS4RGS8 | |
| Hydrochloric Acid SCHEMBL9517520 | 0.83 | KAT2B (0.56) | KAT2BMAPTRGS4RGS8 | |
| SCHEMBL14640429 | 0.81 | KAT2B (0.50) | KAT2BCA12CA1CA9MAPT | |
| SCHEMBL14640440 | 0.81 | KAT2B (0.50) | KAT2BEP300CREBBPKAT2ACA12 | |
| SCHEMBL5593629 | 0.80 | KAT2B (0.49) | KAT2BMAPTKMT2A | |
| SCHEMBL5593574 | 0.77 | KAT2B (0.43) | KAT2B | |
| SCHEMBL14640376 | 0.77 | KAT2B (0.46) | KAT2BMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020128311-A1 | Halocyanoacetamide antimicrobial compositions | GIRONDA KEVIN F (US) | 2002-09-12 | — | — | US | claimed |
| US-5912286-A | Silicone-containing fluoropolymers for controlled release of organic leachants | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 1999-06-15 | — | — | US | claimed |
| EP-0762955-A4 | ANTIFOULING AND FOUL-RELEASE COATINGS | US HEALTH (US) | 1998-01-07 | — | — | EP | claimed |
| EP-0762955-A1 | ANTIFOULING AND FOUL-RELEASE COATINGS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE NAVY (US) | 1997-03-19 | — | — | EP | claimed |
| WO-1995032862-A1 | ANTIFOULING AND FOUL-RELEASE COATINGS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 1995-12-07 | — | — | WO | claimed |
| US-5145501-A | Fungicides, algicides, bactericides | ROHM AND HAAS COMPANY (US) | 1992-09-08 | — | — | US | claimed |
| EP-0147970-B1 | MICROBIOCIDAL OR ANTIMICROBIAL BIOMEDICAL DEVICES | ROHM AND HAAS COMPANY (US) | 1989-03-01 | — | — | EP | claimed |
| US-4542169-A | Biomedical devices containing isothiazolones to control bacteria growth | ROHM AND HAAS COMPANY (US) | 1985-09-17 | — | — | US | claimed |
| EP-0147970-A1 | Microbiocidal or antimicrobial biomedical devices | ROHM AND HAAS COMPANY (US) | 1985-07-10 | — | — | EP | claimed |
| US-4127687-A | PAINTING WITH ISOTHIAZOLONES | ROHM AND HAAS COMPANY (US) | 1978-11-28 | — | — | US | claimed |
| US-12599649-B2 | Bioactive polypeptides for improvements in plant protection, growth and productivity | SPOGEN BIOTECH INC. (US) | 2026-04-14 | — | — | US | disclosed |
| WO-2025242701-A1 | SEED TREATMENT COMPOSITIONS | BASF SE (DE) | 2025-11-27 | — | — | WO | disclosed |
| US-20250351825-A1 | AGRICULTURAL COMPOSITIONS FOR PROTECTING PLANTS AGAINST ABIOTIC STRESSORS | SPOGEN BIOTECH INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250324980-A1 | COMPOSITIONS FOR DELIVERY OF AGENTS INTO PLANT CELLS | OHIO STATE INNOVATION FOUNDATION (US) | 2025-10-23 | — | — | US | disclosed |
| US-12391729-B2 | Fusion proteins, recombinant bacteria, and methods for using recombinant bacteria | SPOGEN BIOTECH INC. (US) | 2025-08-19 | — | — | US | disclosed |
| EP-0147970-B1 | MICROBIOCIDAL OR ANTIMICROBIAL BIOMEDICAL DEVICES | ROHM AND HAAS COMPANY (US) | 1989-03-01 | — | — | EP | disclosed |
| US-4542169-A | Biomedical devices containing isothiazolones to control bacteria growth | ROHM AND HAAS COMPANY (US) | 1985-09-17 | — | — | US | disclosed |
| EP-0147970-A1 | Microbiocidal or antimicrobial biomedical devices | ROHM AND HAAS COMPANY (US) | 1985-07-10 | — | — | EP | disclosed |
| US-4165318-A | AGAINST CHEMICAL DECOMPOSITION OF THE 3-ISOTHIAZOLONE MILDEW CONTROLLING AGENT | ROHM AND HAAS COMPANY (US) | 1979-08-21 | — | — | US | disclosed |
| US-4129448-A | A 3-ISOTHIAZOLONE | ROHM AND HAAS COMPANY (US) | 1978-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12599649-B2 | Bioactive polypeptides for improvements in plant protection, growth and productivity | MAX, VIP, MRTO4 | KAT2B 2768/4885EP300 3062/4885CREBBP 1569/4885 |
| US-20250324980-A1 | COMPOSITIONS FOR DELIVERY OF AGENTS INTO PLANT CELLS | ARGLU1, PHAX, VMA21 | KAT2B 3403/4885EP300 4513/4885CREBBP 3625/4885 |
| US-20020128311-A1 | Halocyanoacetamide antimicrobial compositions | HDHD5, DGKI, DAGLA | KAT2B 1127/4885EP300 218/4885CREBBP 1323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.